Brigham and Women's Hospital at ObesityWeek 2026
Nov 14–17, 2026 National Harbor, MD ~4.4k attendees Website
Brigham and Women's Hospital brings 12 presentations to ObesityWeek 2026 in National Harbor. Its program centers on new obesity therapies and their effect on body composition and lean mass, with posters on ribupatide trial design and elecoglipron in type 2 diabetes. Other work asks how well landmark GLP-1 trials represent U.S. adults and how people report dosing these drugs.
| Organization | ObesityWeek 2026 Attendance |
|---|---|
Brigham and Women's Hospital Boston, MA | |
Harvard-affiliated teaching hospital in Boston, part of Mass General Brigham. | Talk Sat Nov 14 11:55am–12:10pm Changing the Treatment Paradigm in Overweight and Obesity Management Interventional and clinical studiesPopulation health and epidemiologyClinical obesity care and professional practiceMetabolism and integrative physiologyObesity pharmacotherapy and drug development Talk Sat Nov 14 12:10pm–12:35pm Beyond The Scale: The Clinical Relevance of Body Composition, Body Fat Distribution and Lean Mass Interventional and clinical studiesPopulation health and epidemiologyClinical obesity care and professional practiceMetabolism and integrative physiologyObesity pharmacotherapy and drug development Talk Sat Nov 14 1:00pm–1:10pm The Next Frontier: How May New Therapies for Overweight and Obesity Impact Body Composition? Interventional and clinical studiesPopulation health and epidemiologyClinical obesity care and professional practiceMetabolism and integrative physiologyObesity pharmacotherapy and drug development Poster Sat Nov 14 7:30pm–8:30pm Elecoglipron Improves Beta-Cell Function and Insulin Resistance in Adults With Type 2 Diabetes Chronic disease and obesity complicationsObesity pharmacotherapy and drug development Session Sun Nov 15 10:30am–11:30am TOS/KSSO Collaborative Symposium: Unpacking Adipose Tissue - From Basic Biology to Precision Obesity Interventions Covers fat tissue as an active organ, comparing white, brown and beige fat, and links its biology to precision obesity care using biomarkers. Metabolism and integrative physiology Poster Sun Nov 15 2:30pm–3:30pm Rationale and Design of the KaiNETIC-1 and -2 Trials of Ribupatide in People Living With Obesity Obesity pharmacotherapy and drug developmentInterventional and clinical studies Poster Sun Nov 15 2:30pm–3:30pm Novel and off-Label Uses of GLP-1 Receptor Agonists: A Systematized Narrative Review Interventional and clinical studies Poster Sun Nov 15 2:30pm–3:30pm Inpatient Protein-Sparing Modified Fast With/Without Sleeve Gastrectomy in Acute Respiratory Failure Bariatric surgery and devices Poster Sun Nov 15 2:30pm–3:30pm Self-Reported Dosing Behaviors Among US Adults Using GLP-1 RAs for Weight Loss: A Survey Study Obesity pharmacotherapy and drug developmentInterventional and clinical studies Poster Mon Nov 16 2:30pm–3:30pm Associations Between Magnitude of Weight Reduction and Healthcare Resource Utilization Population health and epidemiology Poster Mon Nov 16 2:30pm–3:30pm Representativeness of Five Landmark GLP-1 Receptor Agonist Trials: An NHANES-Based Comparison Policy and public health Poster Mon Nov 16 2:30pm–3:30pm |
Find decision makers at Brigham and Women's Hospital
Tell us what you sell and we’ll find the people at Brigham and Women's Hospital most likely to buy it.
- Who to contact
- Their contact info
- What to say
- Free, no sign-up
Not affiliated with or endorsed by The Obesity Society (TOS), ObesityWeek® or the American Society for Metabolic and Bariatric Surgery (ASMBS). Submit a correction